Comparative efficacy and safety of late non-small cell carcinogens in traditional Chinese medicine:

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide. Although chemotherapy is an important treatment strategy for late-stage non-small cell lung cancer, its effectiveness is influenced by treatment resistance and adverse reactions. Traditional Chinese medicine injections (TCMIs) are widely used as adjunctive therapies; however, the relative efficacy and safety of different TCMI-based therapies remains unclear.

This study aims to compare the efficacy and safety of different Chinese intervention combined chemotherapy and randomized controlled trials (NSCLC) in NSCLC. Through the Chinese databases CNKI, Wanfang, VIP, Chinese Biomedical Literature Database, and the English databases PubMed, Web of Science, and Cochrane Library, relevant information was retrieved from the NSCLC-related trials between January 1, 2021 and May 1, 2026, including test types: randomized controlled trials, intervention trials, test design, control groups, intervention groups, and test results: efficacy, safety, etc. Information.

From the above findings, it can be seen that the study selected NSCLC-related trials, including randomized controlled trials and intervention trials, for a total of 15 trials. These trials were intended to compare the effectiveness and safety of NSCLC-related combined chemotherapy and randomized controlled trials in the NSCLC. It can be seen from the above findings that the study selected NSCLC-related trials, including randomized controlled trials and intervention trials, for a total of 15 trials.

The purpose of these trials was to compare the efficacy and safety of NSCLC in the NSCLC. As can be seen from the above findings, the study selected NSCLC-related trials, including randomized controlled trials and intervention trials, for a total of 15 trials. These trials were intended to compare the therapeutic and safety of NSCLC in the NSCLC.

The purpose of these trials was to compare the effectiveness and safety of NSCLC combined chemotherapy and randomized controlled trials in NSCLC. As can be seen from the above findings, the study selected NSCLC-related trials, including randomized controlled trials and intervention trials, for a total of 15 trials. SPSS is a statistical software for data analysis and statistical modeling, which integrates the Cochrane risk-of-bias tool for risk-prejudice assessment and tools for network evidence assessment such as Confidence in Network Meta-Analysis, CINeMA, and is one of the most widely used methods of risk-prejudice assessment.

If you have any health questions, please consult a professional medical professional.